GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SHL Telemedicine Ltd (NAS:SHLT) » Definitions » 14-Day RSI

SHLT (SHL Telemedicine) 14-Day RSI : 53.03 (As of Dec. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is SHL Telemedicine 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-16), SHL Telemedicine's 14-Day RSI is 53.03.

The industry rank for SHL Telemedicine's 14-Day RSI or its related term are showing as below:

SHLT's 14-Day RSI is ranked worse than
60.42% of 710 companies
in the Healthcare Providers & Services industry
Industry Median: 48.605 vs SHLT: 53.03

Competitive Comparison of SHL Telemedicine's 14-Day RSI

For the Health Information Services subindustry, SHL Telemedicine's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SHL Telemedicine's 14-Day RSI Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where SHL Telemedicine's 14-Day RSI falls into.



SHL Telemedicine  (NAS:SHLT) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SHL Telemedicine  (NAS:SHLT) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


SHL Telemedicine 14-Day RSI Related Terms

Thank you for viewing the detailed overview of SHL Telemedicine's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


SHL Telemedicine Business Description

Traded in Other Exchanges
Address
90 Yigal Alon Street, Tel Aviv, ISR, 67891
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.